Observational Study on CML Patients in Any Phase of the Disease Treated With Ponatinib (Iclusig®)
NCT ID: NCT04048564
Last Updated: 2023-09-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
120 participants
OBSERVATIONAL
2018-02-23
2023-07-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Observational Study on Chronic Myeloid Leukemia Patients in Any Phase Treated With Ponatinib (Iclusig®) at Any Dose
NCT03933852
Iclusig® (Ponatinib) in Clinical Practice for the Treatment of Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia in Belgium
NCT03678454
An Observational Registry to Evaluate the Incidence of and Risk Factors for Vascular Occlusive Events Associated With ICLUSIG®
NCT02455024
A Study to Evaluate Effectiveness and Safety of Ponatinib in Patients With BCR-ABL Positive ALL in Standard Clinical Practice in Europe - "POSEIDON"
NCT03515785
Safety and Efficacy of Ponatinib Followed by Imatinib in Patients With Chronic Myelogenous Leukemia in Chronic Phase
NCT04070443
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Having initiated for less than six months a treatment with ponatinib.
* The ability to understand the requirements of the study and to comply with the study data collection procedures.
Exclusion Criteria
* Patients receiving an investigational agent.
* Patients who are pregnant and/or breastfeeding.
* Patients with contraindications for Ponatinib according to Summary of Products Characteristics.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Incyte BioSciences France
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ali G. Turnan, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Paris Sud University Hospitals-Bicetre
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU SUD Reunion GHSR
Saint-Pierre, Reunion, France
CHU Amiens-Picardie- Site SUD
Amiens, , France
CHU D'Angers
Angers, , France
CH Annecy
Annecy, , France
Centre Hospitalier Argenteuil
Argenteuil, , France
Centre Hospitalier D'Avignon
Avignon, , France
CH Beziers
Béziers, , France
Institut Bergonie
Bordeaux, , France
Cabinet D'hematologie De La Clinique Du Parc
Castelnau-le-Lez, , France
CH William Morey
Chalon-sur-Saône, , France
CH Chambery
Chambéry, , France
CHU Estaing Clermont Ferrand
Clermont-Ferrand, , France
CHU Dijon, François Mitterrand
Dijon, , France
Centre Hospitalier De Dunkerque
Dunkirk, , France
Centre Hospitalier Departemental Vendee
La Roche-sur-Yon, , France
CH De Versailles (Andre Mignot)
Le Chesnay, , France
Hopital Bicetre
Le Kremlin-Bicêtre, , France
CH De Libourne
Libourne, , France
CHRU De Lille - Hôpital Huriez
Lille, , France
CH Limoges
Limoges, , France
Leon Berard, Lyon
Lyon, , France
Centre Hospitalier De Meaux
Meaux, , France
Hopitaux Prives Metz Centre De Belle-Isle
Metz, , France
CH De Metz (Hopital De Mercy - CHR Metz Thionville)
Metz, , France
CHU Montpellier
Montpellier, , France
Hopital Salpetriere
Paris, , France
La Pitié Salpêtrière - Paris
Paris, , France
Hopital Necker
Paris, , France
CH St Jean
Perpignan, , France
CHU De Poitiers
Poitiers, , France
Hôpital Rene Dubos
Pontoise, , France
CH De Cornouaille
Quimper, , France
CHU De Rennes
Rennes, , France
Hopital Victor Provo
Roubaix, , France
La Clinique Sainte-Anne
Strasbourg, , France
CHRU Strasbourg
Strasbourg, , France
Institut Universitaire Du Cancer Toulouse - Oncopo
Toulouse, , France
CH Troyes
Troyes, , France
CHRU De Nancy - Hôpitaux De Brabois
Vandœuvre-lès-Nancy, , France
CHU Sud, St Pierre - La Réunion
Vandœuvre-lès-Nancy, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Huguet F, Guerci-Bresler A, Roth-Guepin G, Cayssials E, Slama B, Santagostino A, Penot A, Quittet P, Cony-Makhoul P, Saad A, Bastie JN, Hacini M, Coiteux V, Uzunov M, Roy L, Le Clech L, Berger M, Agneray AM, Messas E, Etienne G, Turhan A, Nicolini FE, Rousselot P. Clinical outcomes in patients in any phase of CML treated with ponatinib in France-Data from the TOPASE observational study. Br J Haematol. 2024 Dec;205(6):2295-2304. doi: 10.1111/bjh.19819. Epub 2024 Nov 6.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2017-A01355-48
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.